In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $71.35 in the prior trading day, Avidity Biosciences Inc (NASDAQ: RNA) closed at $71.6, up 0.35%. In other words, the price has increased by $0.35 from its previous closing price. On the day, 1.81 million shares were traded. RNA stock price reached its highest trading level at $71.66 during the session, while it also had its lowest trading level at $71.34.
Ratios:
Our goal is to gain a better understanding of RNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.57 and its Current Ratio is at 11.57. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Roth Capital on September 17, 2025, initiated with a Buy rating and assigned the stock a target price of $62. On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.Bernstein initiated its Outperform rating on June 24, 2025, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 22 ’25 when Hughes Steven George sold 2,209 shares for $47.54 per share. The transaction valued at 105,015 led to the insider holds 38,867 shares of the business.
McCarthy Teresa sold 20,000 shares of RNA for $1,003,058 on Oct 15 ’25. The Chief Human Resources Officer now owns 97,130 shares after completing the transaction at $50.15 per share. On Oct 03 ’25, another insider, Mosbrooker Eric, who serves as the Chief Commercial Officer of the company, sold 6,562 shares for $45.38 each. As a result, the insider received 297,771 and left with 55,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 10788382720 and an Enterprise Value of 8962512896. For the stock, the TTM Price-to-Sale (P/S) ratio is 516.93 while its Price-to-Book (P/B) ratio in mrq is 5.57. Its current Enterprise Value per Revenue stands at 429.486 whereas that against EBITDA is -14.715.
Stock Price History:
The Beta on a monthly basis for RNA is 0.96, which has changed by 1.2037549 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $71.79, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 13.51%, while the 200-Day Moving Average is calculated to be 71.62%.
Shares Statistics:
The stock has traded on average 5.17M shares per day over the past 3-months and 2324690 shares per day over the last 10 days, according to various share statistics. A total of 146.77M shares are outstanding, with a floating share count of 138.18M. Insiders hold about 8.29% of the company’s shares, while institutions hold 95.55% stake in the company. Shares short for RNA as of 1764288000 were 8865578 with a Short Ratio of 1.71, compared to 1761868800 on 10497758. Therefore, it implies a Short% of Shares Outstanding of 8865578 and a Short% of Float of 5.9299998.
Earnings Estimates
Investors are keenly observing as 10.0 analysts analyze and rate. The current performance of Avidity Biosciences Inc (RNA) in the stock market.The consensus estimate for the next quarter is -$1.28, with high estimates of -$0.98 and low estimates of -$1.59.
Analysts are recommending an EPS of between -$3.62 and -$5.16 for the fiscal current year, implying an average EPS of -$4.49. EPS for the following year is -$4.9, with 14.0 analysts recommending between -$3.24 and -$6.53.
Revenue Estimates
13 analysts predict $1.98M in revenue for. The current quarter. It ranges from a high estimate of $12.5M to a low estimate of -$6.5M. As of. The current estimate, Avidity Biosciences Inc’s year-ago sales were $2.97M
A total of 11 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $30.4M, while the lowest revenue estimate was $11.4M, resulting in an average revenue estimate of $20.33M. In the same quarter a year ago, actual revenue was $10.9M
